Industry News
Biotechnology Industry News

Kailera is taking another step…
Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, with proceeds intended to advance its GLP-1 assets through clinical development.
Spyre Therapeutics’ monoclonal…
Spyre Therapeutics’ monoclonal antibody hit the key goal in a phase 2 study for ulcerative colitis, which the company has touted as proof it can best Takeda’s Entyvio.
AbbVie has agreed to pay $30…
AbbVie has agreed to pay $30 million upfront to Chinese biotech Haisco Pharmaceutical Group for two non-opioid pain treatment candidates.
A phase 2/3 trial of Ideaya…
A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of the year.
Revolution Medicines’ pan-RAS…
Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
The fight for two tumor types is…
The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca and SynOx Therapeutics planning to enter a market served by companies including Daiichi Sankyo on the back
With its latest obesity play…
With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals.
Cema-cel eradicated minimal…
Cema-cel eradicated minimal residual disease in seven of 12 patients, compared to two of 12 participants in the observational control arm.
Seaport Therapeutics and Hemab…
Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.
Boehringer Ingelheim and Amgen…
Boehringer Ingelheim and Amgen have both canned early-stage immunology candidates after the prospects showed little clinical promise.
The second time is not the charm…
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted application.
Oricell Therapeutics has now…
Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public.
When Fierce last caught up with…
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of antibody-drug
The Orano group has selected a new…
The Orano group has selected a new leader for its oncology-focused Orano Med subsidiary in Frederic Desdouits, who has sat on the governance board of the company since 2022. Desdouits’ appointment was attributed to his
Many gene therapy outfits focus on…
Many gene therapy outfits focus on technical advances, Ocugen CEO Shankar Musunuri, Ph.D., said, meaning they miss out on broader commercial success.
Bioprocessing is evolving rapidly…
Bioprocessing is evolving rapidly in a shifting landscape of innovative and complex products, processes and technologies. In this new era, three important trends are materializing—and there’s a critical (but perhaps unsung) enabler to thank for
Gilead has tucked another drug…
Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise its option on Kymera Therapeutics’ preclinical anticancer molecular glue degrader.
Avalyn Pharma is eyeing an IPO as…
Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung conditions into phase 3 trials.
NAMs are no longer theoretical….
NAMs are no longer theoretical. The real challenge now is choosing the right tools—and generating data that holds up when it counts.
Join global leaders at ASGH 2026…
Join global leaders at ASGH 2026 to bridge the gap between lab breakthroughs and market execution while unlocking growth in Asia’s health economy.

